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ABSTRACT
Objectives: Tumour recurrence of glioblastoma
multiforme (GBM) after initial treatment with surgical
resection, radiotherapy and chemotherapy is an inevitable
phenomenon. This retrospective cohort study compared
the efficacy of interstitial high dose rate brachytherapy
(HDR-BRT), re-resection and sole dose dense
temozolomide chemotherapy (ddTMZ) in the treatment of
recurrent glioblastoma after initial surgery and
radiochemotherapy.
Design: Retropective cohort study.
Setting: Primary level of care with two participating
centres. The geographical location was central Germany.
Participants: From January 2005 to December 2010, a
total of 111 patients developed recurrent GBM after initial
surgery and radiotherapy with concomitant temozolomide.
The inclusion criteria were as follows: (1) histology-proven
diagnosis of primary GBM (WHO grade 4), (2) primary
treatment with resection and radiochemotherapy, and (3)
tumour recurrence/progression.
Interventions: This study compared retrospectively the
efficacy of interstitial HDR-BRT, re-resection and ddTMZ
alone in the treatment of recurrent glioblastoma.
Primary and secondary outcome measures: Median
survival, progression free survival and complication rate.
Results: Median survival after salvage therapy of the
recurrence was 37, 30 and 26 weeks, respectively. The
HDR-BRT group did significantly better than both the
reoperation (p<0.05) and the ddTMZ groups (p<0.05).
Moderate to severe complications in the HDR-BRT,
reoperation and sole chemotherapy groups occurred in
5/50 (10%), 4/36 (11%) and 9/25 (36%) cases,
respectively.
Conclusions: CT-guided interstitial HDR-BRT attained
higher survival benefits in the management of recurrent
glioblastoma after initial surgery and radiotherapy with
concurrent temozolomide in comparison with the other
treatment modalities. The low risk of complications of the
HDR-BRT and the fact that it can be delivered
percutaneously in local anaesthesia render it a promissing
treatment option for selected patients which should be
further evaluated.
INRODUCTION
Glioblastoma multiforme (GBM) is the most
common of all gliomas and the most malig-
nant primary brain tumour. Despite multimod-
ality initial treatment with gross total removal,
radiotherapy and chemotherapy, the prognosis
of GBM remains poor
1 and the reported
median survival is about 14–18 months.
2
Tumour recurrence is observed in almost all
patients. The treatment algorithm for recur-
rent glioblastoma varies from centre to centre,
and there is not yet a consensus on the most
appropriate treatment for this devastating
disease. Non-surgical treatment such as inten-
sive temozolomide chemotherapy is, at best, a
treatment option after which long-term sur-
vival is seldom observed.
34Dose dense temo-
zolomide treatment (ddTMZ), as 1 week
on/1 week off regimen, did not show superior
efﬁcacy as compared with the standard day
every 4 weeks schedule.
5 New agents such as
ARTICLE SUMMARY
Article focus
▪ Analyse survival rates after salvage treatment of
recurrent glioblastoma.
▪ Compare the efficacy of interstitial high dose rate
brachytherapy (HDR-BRT), re-resection and dose
dense temozolomide chemotherapy (ddTMZ)
alone in the treatment of recurrent glioblastoma.
▪ To report mature results of long-term follow-up,
outcomes and toxicity.
Key messages
▪ HDR-BRT is a safe alternative for salvage treat-
ment of recurrent glioblastoma.
▪ The HDR-BRT group did significantly better than
both the reoperation and the ddTMZ groups.
Strengths and limitations of this study
▪ Non-randomisation regarding choices of treat-
ment and selection bias.
Archavlis E, Tselis N, Birn G, et al. BMJ Open 2013;3:e002262. doi:10.1136/bmjopen-2012-002262 1
Open Access Research
  group.bmj.com  on May 13, 2013 - Published by  bmjopen.bmj.com Downloaded from bevacizumab are being tested as single agent chemother-
apy or in combination with other drugs.
6 Resurgery is
sometimes recommended and probably produces the
better survival results but also carries associated risks.
7
Studies have shown that the extent or completeness of
resection have been correlated with survival.
89Previous
studies have retrospectively assessed outcomes of patients
after recurrent glioblastoma tumour resection,
10–13 and
tried to develop prognostic scoring systems to predict sur-
vival after surgery.
7 However, surgical resection is not a
good option in many patients in the recurrent
setting, given the extent of the recurrent tumour and the
proximity to eloquent neurological structures. Another
feasible treatment option that can play an important role
in providing palliation is the interstitial high dose rate
brachytherapy (HDR-BRT) consisting of an afterloading
192Ir implant, which is applicable even to patients with
extended recurrent tumours and can be delivered via the
percutaneous approach with CT guidance.
14 15
The aim of this retrospective study was to describe
the survival rates and 3-month radiographic response
to treatment for recurrence of glioblastoma, with
either HDR-BRT, resurgery or intensive temozolomide
chemotherapy, acknowledging selection bias over
which one of the three salvage therapies was chosen.
Despite its methodological and conseptual limitations
due to its retrospective nature, this report gives a full
account of consecutive patients with recurrent glio-
blastoma treated in our departments with HDR-BRT or
resurgery or sole ddTMZ and provides survival rates,
as well as compares and contrasts the outcomes and
complication rates between the three different groups
of salvage treatment.
PATIENTS AND METHODS
We conducted a retrospective analysis from consecutive
patients with recurrent glioblastoma after initial
surgery and radiotherapy with concomitant temozolo-
mide who were admitted in our hospital between
January 2005 and December 2010. This study was
approved by the institutional research ethics board.
Among the 115 patients with glioblastoma recurrence,
111 patients underwent either HDR-BRT, re-resection
or ddTMZ as a salvage treatment, and they formed the
focus of interest in this study. Prospectively collected
data on patient characteristics, clinicopathological fea-
tures and survival outcomes were reviewed. The
primary endpoint of the study was disease-speciﬁcs u r -
vival. Secondary endpoints were complication rates,
adverse events and radiographic response to salvage
therapy. All the patients had received previous surgery
as primary treatment for initial histology-proven glio-
blastoma (WHO grade 4), and gross total resection
was performed in 81/111 (73%) and subtotal resec-
tion in 30/111 patients (27%). All the patients were
given postoperative partial-brain irradiation with a
focal dose of up to 60 Gy, and the median interval
from the date of surgery until the start of radiotherapy
was 24 days (6–58 days). All the patients received temo-
zolomide chemotherapy as part of their initial
treatment.
The inclusion criteria were as follows: (1) histology-
proven diagnosis of glioblastoma (WHO grade 4),
(2) primary treatment with resection and radioche-
motherapy, and (3) tumour recurrence/progression.
The exclusion criteria for this study formed simultan-
eously the contraindications for further treatment:
(1) patients with poor neurological function Karnofsky
performance score (KPS) <70 and (2) patients with
consciousness impairment were considered ineligible.
No case of secondary GBM was included.
The median recurrent tumour volume in all groups
was 46 cm³ (3–207 cm³). The HDR-BRT consisted of an
afterloading
192Ir implant which delivered a median
dose of 40 Gy (30–50) at twice-daily fractions of 5.0 Gy
to a CT-MRI fusion-deﬁned planing treatment volume.
Catheter implantation was implemented using inter-
active CT guidance under local anaesthesia and sedoa-
nalgesia and the median catheter number was 7 (1–21).
A detailed description of the implantation technique
and brachytherapy planning can be found in our previ-
ous reports in the literature.
14 15
Patients in the surgical arm underwent a maximal
safe surgical resection of their recurrent tumours.
Resurgery and HDR-BRT were followed by TMZ
chemotherapy as an adjunctive treatment with a dose
of 100 mg/m
2 for 5 days in a 28-day cycle. Of course,
the rechallenge of these patient groups with TMZ con-
founds interpretation of the results but we considered
not to withhold such a therapy from a patient popula-
tion with this devastating disease.
In patients treated with sole chemotherapy, we used
the 1 week on/1 week off temozolomide with a daily
dose of 150 mg/m², until documented disease progres-
sion or unacceptable toxicity. We chose this more rigor-
ous dose regimen of TMZ according to the publications
of Wick et al
16 who reported a progression-free survival
(PFS) as high as 48% with an overall survival for
12 months of 81% Toxicity was evaluated according to
the Common Terminology Criteria for Adverse Events
(CTCAE; V.3.0). In case of haematological toxicity grade
4 or non-haematological toxicity grade 3, the dosage
TMZ of the next cycle was reduced by 25 mg/m²/day. In
case of CTCAE grade 4 non-haematological toxicity, the
patient stopped treatment. In case of a grade 4 haemato-
logical toxicity or a grade 3 non-haematological toxicity
at dose level of 75 mg/m²/day, the patient went off treat-
ment. In case of dose reductions, dose re-escalation was
not allowed. Blood examinations were done on day 15
and day 29 and when platelets were above 100×10
9/l
and neutrophils counts above 1.5×10
9/l, the following
7 days TMZ was administered. Otherwise treatment was
postponed until recovery to CTCAE grade 1 and/or pla-
telets were above 100×10
9/l. The treatment was stopped
if it had to be postponed for more than 4 weeks.
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The follow-up protocol for patients with glioblastoma in
our centre consisted of MRI of the brain not later than
48 h after tumour resection. Surveillance for tumour
recurrence was conducted using MRI scans 8 weeks after
radiochemotherapy and thereafter, every 3 months.
Glioblastoma recurrence is deﬁned as the appearance or
enlargement since prior imaging, of a contrast-enhancing
mass on T1-weightedMRI. Differentiating tumour recur-
rence from radiation necrosis can be difﬁcult, for this task
we used effectively in some cases positron emission tomog-
raphy, MR spectroscopy and MR perfusion. In cases where
these data were not useful, we obtained a stereotactic
biopsy.
Radiographic response to therapy was evaluated at
3 months after starting the salvage treatment using the
Macdonald criteria.
17 These criteria use the largest cross-
sectional area of the postcontrast images, neurological
status and corticosteroid dose. Complete response (CR)
was deﬁned as complete disappearance of measurable
disease by MRI, partial response (PR) as 50% decrease
in the area of enhancement and progressive disease
(PD) as >25% increase in the area of enhancement,
appearance of a new lesion or deterioration in clinical
status, probably secondary to tumour progression.
Patients with CR or PR had to be on the same or
decreased steroid dose and have stable or improved
neurological ﬁndings. Stable disease (SD) is deﬁned for
patients not fulﬁlling CR, PR or PD criteria.
Selection criteria for HDR-BRT, re-resection or ddTMZ as
a salvage treatment
Only patients with recurrent tumours in areas not trad-
itionally considered eloquent brain regions were
included for re-resection. It was generally avoided in the
presence of (1) affected basal ganglia, and/or (2) an
involvement of eloquent/critical brain areas: the pre-
sumed motor area, the presumed speech area, (3) a
platelet count <100×10
9/l and/or leuopaenia <4/nl, sig-
nifying myelosuppression after chemotherapy.
Extension of tumour recurrence in more than two
lobes, multilocality of recurrence and affection of both
hemispheres would discourage neurosurgeons to treat
with resurgery. HDR brachytherapy and ddTMZ were
selected for recurrent tumour independently from
tumour location or extent. All patients were considered
in our oncological conference, after careful analysis of
the radiological studies and clinical factors, the multidis-
ciplinary team of neurosurgeons, radiotherapists and
neuroradiologists developed the treatment plan. The
study was based on different policies of treatment.
Allocation to HDR-BRT, re-resection or ddTMZ was not
randomised. The best approach involved collaborative
interactions and decisions made by the team. If contro-
versy existed, and provided that the above selection cri-
teria are fullﬁlled, resurgery was considered as the ﬁrst
treatment choice. Patients were generally not considered
for treatment unless their KPS was ≥70.
Stereotactic biopsy for histological conﬁrmation was
performed in all patients included in this study. All the
patients were informed about the pros and cons of
salvage therapy modalities. Many patients refused
further treatment options and among alternatives of sup-
portive care, intensive temozolomide chemotherapy was
offered as salvage treatment (n=23).
Treatment planning in HDR-BRT was devised to deliver
60 Gy to the edge of a volume that extends 1 cm beyond
the contrast-enhancing tumour, with variations included
to spare radiosensitive structures (eg, optic chiasm).
Statistical analysis
Continuous variables were expressed in medians (IQR)
and compared using the Mann-Whitney U test. Categorical
variables were compared with the χ
2 test or Fisher’se x a c t
test when appropriate. Overall survival and median PFS of
the three study groups were estimated by the Kaplan-Meier
method. Comparison of survival between groups was per-
formed with the log-rank test. Median PFS after treatment
of glioblastoma recurrence was deﬁned as the period from
t h ed a t eo ft r e a t m e n to fr e c u r r e n tg l i o b l a s t o m at ot h ed a t e
of the second tumour recurrence, progression or death.
Overall survival was deﬁned as the period from the date of
ﬁrst surgery for glioblastoma to the date of death related to
any cause. A p value ≤0.05 was considered to be signiﬁcant.
Statistical analysis was performed using the BiAS computer
software program.
RESULTS
The median follow-up duration was 49 months
(11–61 months). Table 1 shows the patients’ characteristics
and KPS proﬁles at the time of glioblastoma recurrence.
The three groups had similar KPS rates and a similar inci-
dence of comorbid illness. Patients in the HDR-BRT group
were older than those in the re-resection and chemother-
apy groups but this difference was not statistically
signiﬁcant.
All patients in the re-resection group had recurrent
tumours not invading the eloquent regions, whereas
74% of patients in the brachytherapy group had some
kind of affection of the presumed motor area, the pre-
sumed speech area and basal ganglia. Pretreatment
laboratory investigations at the time of recurrence were
comparable for the three groups except that 10%
patients in the HDR-BRT group had a lower white blood
cell count level. With regard to the extent of resection
of the primary pathology (gross total vs subtotal) and
tumour volume of the primary group the three groups
shared similar features. The HDR-BRT group, however,
had a larger recurrent tumour size than the re-resection
and ddTMZ groups (51 vs 43 vs 45 cm³), suggesting that
the size of tumour recurrence played an important role
in aggressiveness of treatment. Time to develop ﬁrst
recurrence was similar in all groups (12.2 vs 8.7 vs
9.1 months). O-6-methylguanine-DNA methyltransferase
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(33/111 patients) and was similar in the three groups.
Table 2 showed the complication rates of patients
undergoing HDR-BRT, re-resection and ddTMZ alone
as salvage treatment. Six patients developed
procedure-related morbidities in the HDR-BRT group.
Among those, two developed intracerebral bleeding
after catheter implantation and one of them died due to
massive haemorrhage. One patient developed bacterial
meningitis postexplantation, and was treated successfully
with antibiotics. Symptomatic radiation necrosis
occurred in two cases and manifested several months
after brachytherapy. They were managed conservatively,
either by corticosteroid or by intravenous mannitol.
Four patients in the resurgery group developed
procedure-related morbidities and two patients succumbed
during the same hospital admission. Nine patients in the
ddTMZ group developed procedure-related morbidities.
One patient developed pneumocystis carinii pneumonia
and died. Eight patients discontinued TMZ because of tox-
icity: grade 4 thrombocytopaenia (4), persistent grade 4
leucopaenia (3) and grade 4 elevated transaminases (1).
The incidences of procedure-related morbidity and hos-
pital mortality between HDR-BRT and reoperation groups
Table 2 Complication rates
HDR-BRT group (n: 50) Resurgery group (n: 36) ddTMZ alone group (n: 25)
Complications No. of patients No. of patients No. of patients
Wound healing disturbance 0 1 0
Intracerebral bleeding 2 2 0
Bacterial mengitis 1 1 0
Radiation necrosis 2 0 0
Severe infections 0 0 1
Severe toxicity 0 0 8
Overall complications 5 (10%) 4 (11%) 9 (36%)
ddTMZ, dose dense temozolomide chemotherapy; HDR-BRT, high dose rate brachytherapy.
Table 1 Demographic, clinical and radiographic characteristics of patients with recurrent glioblastoma*
Parameters HDR-BRT group Resurgery group ddTMZ
No. of cases 50 36 25
Age (in years) 57 54 56
Sex (female), n (%) (no. of cases) 21 (43%) 17 (47%) 11 (44%)
Standard follow-up (range) (in months) 49 (11–61) 46 (11–61) 51 (11–61)
KPS 90 90 90
100 8 4 5
90 3 18 12
80 14 10 5
70 5 4 2
Time since initial diagnosis (in months) 12.2 8.7 9.1
Side of tumour location
Left 39 10 15
Right 11 26 10
Predominant lobe of tumour location (no. of cases)
Frontal 9 16 2
Temporal 16 9 7
Parietal 15 4 6
Occcipital 11 7 10
Eloquent/critical regions involved (no. of cases)
01 3 3 6 4
11 9 0 1 6
21 3 0 3
35 0 2
Tumour volume (cm³) 51 43 45
Seizures (no. of cases)
Yes 27 21 12
No 23 15 13
*Mean values are presented as means ±SD.
ddTMZ, dose dense temozolomide chemotherapy; HDR-BRT, high dose rate brachytherapy; KPS, Karnofsky performance score.
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higher complication rate in the ddTMZ group was due to
increased toxicity. Adverse events of all treatment groups
due to toxicity are summarised in table 3.
Overall survival was deﬁned as the time from primary
surgery to the time of death or last follow-up. After a
median follow-up of 49 months, the median overall sur-
vival was 82 weeks in the HDR-BRT group, 64 weeks in
the resurgical group and 48 weeks in the sole chemo-
therapy group whereas the median survival after salvage
therapy of the recurrence was 37, 30 and 24 weeks,
respectively (Kaplan-Meier survival curves in ﬁgure 1).
The HDR-BRT group did signiﬁcantly better than both
the reoperation (p<0.05) and the chemotherapy groups
(p<0.05).
The radiographic response rate (CR and PR), using
the Macdonald criteria, 3 months after initiation of the
salvage therapy was 24% in the HDR-BRT group, 28% in
the resurgical group and 8% in the ddTMZ alone group
(Table 4). The baseline scan was the MRI within the ﬁrst
48 h after the initial treatment (primary surgery) which
was compared with the MRI scan at 3 months after the
initiation of the salvage treatment.
The time to develop progression (PFS) was 32 weeks in
the HDR-BRT group, 21 weeks in the resurgical group and
15 weeks in the chemotherapy alone group. By excluding
recurrent tumours with volume larger than 30 ml (n=76,
68%) and tumours that were subtotal resected (n=30,
Table 3 Adverse events due to toxicity in different treatment groups
Parameters HDR-BRT group Resurgery group ddTMZ
No. of cases 50 36 25
Nausea
Grade 1/2 5 3 4
Grade 3/4 0 0 0
Vomiting
Grade 1/2 1 1 1
Grade 3/4 0 0 0
Diarrhoea
Grade 1/2 0 0 1
Grade 3/4 0 0 0
Constipation
Grade 1/2 0 0 1
Grade 3/4 0 0 0
Loss of appetite
Grade 1/2 4 2 4
Grade 3/4 0 0 0
Fatigue
Grade 1/2 6 4 4
Grade 3/4 0 0 0
Thrombocytopaenia
Grade 1/2 6 6 2
Grade 3/4 0 0 4
Leucopaenia
Grade 1/2 4 5 4
Grade 3/4 0 0 3
Elevated transaminases
Grade 1/2 0 0 1
Grade 3/4 0 0 1
Infection
Grade 1/2 3 2 1
Grade 3/4 0 0 1
ddTMZ, dose dense temozolomide chemotherapy; HDR-BRT, high dose rate brachytherapy.
Figure 1 Kaplan-Meier survival analysis after salvage
therapy.
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times to develop progression were extended in the
re-resection and sole chemotherapy groups to 24 and
18 months, respectively but were not signiﬁcantly different
in the HDR-BRT. The survival rate after HDR-BRTwas also
independent of age (≤50 years vs >50 years). In the sub-
group of patients ≤50 years we observed an extension of
the PFS in the re-resection and sole chemotherapy groups
to 25 and 19 months, respectively.
The PFS-6 rate after treatment of glioblastoma recur-
rence in the HDR-BRT group was 64%. The correspond-
ing rates in the re-resection and sole chemotherapy
groups were 41% and 29%.
Univariate analysis of ﬁve clinical and radiological para-
meters (Table 5) showed that time to progression after
ﬁrst treatment and time to the second recurrence (pro-
gression) after treatment of the ﬁrst recurrence were sig-
niﬁcant clinical factors that adversely affected overall
survival in all groups. Age (≤50 years vs >50 years) and
tumour volume (≤30 vs >30 ml) affected overall survival
only in the resurgery and sole chemotherapy groups. In
the multivariate analysis, recurrence with tumour volume
of more than 30 ml, age >50 years remained an independ-
ent unfavourable prognostic factor for overall survival in
the resurgery and sole chemotherapy groups (p<0.05).
The median KPS of the entire patient population was
80 at the time of salvage treatment. At the ﬁrst 2-month
evaluation periods, the median KPS was 80 for the
HDR-BRT group, 70 for the resurgery group and 70 for
the sole chemotherapy group, respectively. Therefore,
there was no severe deterioration regarding function in
the ﬁrst 2 months immediately following salvage treat-
ment in any of the groups.
DISCUSSION
Salvage treatment of recurrent glioblastoma with
HDR-BRTachieved in this retrospective study a better sur-
vival outcome and comparable radiographic response and
complication rates in comparison to those seen with
re-resection or ddTMZ.
Table 5 Clinical and radiological parameters
Median overall survival (weeks)
HDR-BRT Resurgery ddTMZ
Time to recurrence/progression
After initial suregry
<6 months 74* 51* 39*
≥6 months 85* 73* 59*
Time to second recurrence/progression
After salvage treatment (HDR-BRT or resurgery or ddTMZ)
<3 months 39* 36* 31*
≥3 months 83* 69* 53*
Age
<50 years 82 71* 51*
≥50 years 79 60* 31*
Tumour volume
<30 ml 84 73* 52*
≥30 ml 81 66* 41*
Eloquent regions involved
Yes 79 46
No 82 64 49
*Asterisks denote significant difference in median overall survival (p<0.05) between subgroups of patients.
ddTMZ, dose dense temozolomide chemotherapy; HDR-BRT, high dose rate brachytherapy.
Table 4 Radiographic response in patients with recurrent glioblastoma, 3 months after initiation of the salvage treatment
HDR-BRT group (n: 50) Resurgery group (n: 36) ddTMZ alone group (n: 25)
Characteristic No. of patients (%) No. of patients (%) No. of patients (%)
Complete response 2 (4) 4 (11) 0
Partial response 10 (20) 6 (17) 2 (8)
Stable disease 22 (44) 14 (39) 9 (36)
Progressive disease 13 (26) 9 (25) 9 (36)
Not evaluable 3 (6) 3 (8) 5 (20)
*Resurgery and HDR-BRT were followed by TMZ chemotherapy as an adjunctive treatment with a dose of 100 mg/m
2 for 5 days in a 28-day
cycle.
ddTMZ, dose dense temozolomide chemotherapy; HDR-BRT, high dose rate brachytherapy.
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the reﬁnements of surgical techniques by using 5-aminole-
vulinic acid for ﬂuorescence-guided surgery over the
past years, the reported median survival is about
14–18 months.
2 Nonetheless, treating the patients in an
attempt to improve the quality of life and longevity is of
utmost importance. Tumour recurrence is common, with a
2-year survival rate of only 2.2%.
16 In all, survival time after
manifestation of recurrence is extremely limited,
10 18
hence it is important for neurosurgeons to select the most
appropriate treatment for patients with recurrent glioblast-
oma. Variables of the primary surgery predicting longer
survival in several studies include extent of resection (gross
total), younger age (<50 years), higher KPS, normal
mental status, smaller tumour volume and MGMT
methylation.
71 9
Treatment of glioblastoma recurrence poses several
technical challenges, including bigger tumour volumes,
signiﬁcant gliosis and adhesions from the previous oper-
ation and proximity of the tumour to eloquent brain
areas. The latter may be a condition which is a relative
contraindication to re-resection. Surgery, if attempted, and
usually in combination with other regimens, has limited
success, while the risk of mortality and postoperative mor-
bidity is high.
11 12 Similarly, chemotherapy as sole treat-
ment for recurrent glioblastoma
20 21 gives predominantly
unsatisfactory results. On the other hand, Wick et al have
shown that a rigorous regimen (150 mg/m² daily on a
week on/week off cycle) may yield a PFS of 6 months as
high as 48% with an overall survival for 12 months of 81%.
We decided to use temozolomide in this recurrent setting
because it is well tolerated, has good oral bioavailability
and is convenient to administer as an outpatient regimen.
Our study showed a lower beneﬁt of ddTMZ in recurrent
glioblastoma in comparison to other treatment modalities.
Of course, one may assume that the majority of these
patients would have an unmethylated MGMT promoter.
Thus, if ddTMZ would have been effective in overcoming
that resistance, one would expect a more favourable
outcome in these patients, regardless of the MGMT pro-
moter status. Other trials also expressed doubt on the use-
fulness of intensiﬁed dosing regimens.
5
In view of the limited success rates of surgery and
chemotherapy, the role of reirradiation, stereotactic
radiosurgery and BRT is gaining more importance.
Gutin et al suggested that brachytherapy is promising for
certain recurrent malignant gliomas. The authors
implanted temporarily
125I sources using stereotactic
techniques.
22 However, radiation necrosis dampened the
results of HDR temporary
125I seed implants which also
require a stereotactic frame placement for seed delivery.
Repeated operations for radionecrosis were observed
and may be explained by inhomogeneous dose distribu-
tion and slight migration of seeds over time. Previous
studies show the effectiveness of fractionated stereotactic
radiosurgery (FSRS) as an option for treatment of recur-
rent glioblastoma.
23–25 Combs et al
23 reported 5 months
PFS after FSRS and 21 months median overall survival.
However, SRS is not recommended for recurrent lesions
>40 mm in diameter
26 and the fulﬁlment of this restric-
tion immensely limits patient’s eligibility for treatment.
Low dose rate (LDR)-BRT is an applied method to
deliver additional dose while sparing healthy tissue.
27 28
In a previous study we demonstrated a signiﬁcant
improvement in overall survival after HDR-BRT.
14 In
spite of notably larger tumour size in comparison to pre-
vious seed, LDR and SRS trials and expanded eligibility
criteria, the results were encouraging. Furthermore, the
radiobiological advantages of HDR-BRT in comparisson
to the other treatment modalities are due to shorter
treatment duration and higher isodoses (eg, >150%) in
the main/central part of the target volume. Despite the
retrospective nature and selection bias of this study we
aimed to offer data on survival rates of different treat-
ment groups and to facilitate decision making for
salvage treatment on recurrent glioblastoma.
Our present study showed that HDR-BRT could
achieve better long-term survival outcomes to those seen
with re-resection and sole temozolomide chemotherapy
in patients with recurrent glioblastoma. It is obvious that
a retrospective comparison with HDR-BRT with resur-
gery and ddTMZ on which the above conclusions are
drawn is complicated by bias of patient selection.
Although the cases of HDR-BRT group included in this
study were more demanding because of bigger tumour
volumes and involvement of eloquent regions, this,
however, did not translate into increased perioperative
morbidity and mortality or complication rates compared
with resurgery. After excluding confounding factors
(incomplete resection of recurrent tumour) for further
progression, the survival beneﬁt of HDR-BRT remained
unchanged. There are several reasons why HDR-BRT is
a promising treatment option for glioblastoma recur-
rence. First, HDR-BRT can be delivered percutaneously,
under local anaesthesia and sedoanalgesia, thereby
avoiding a second operation. Second, HDR-BRT is
applicable even to tumours proximal to eloquent brain
areas. Third, HDR-BRT has the ability to precisely
deliver high doses of radiation even in large tumour
volumes, exploiting the radiobiological advantage of
fractionation over a period of 4 days, and thus minimis-
ing the risk of serious side effects. Fourth, HDR-BRT for
recurrent disease using
192Ir implants through interstitial
placed catheters has been shown to improve median sur-
vival in selected patients to around 8 months.
42 9Fifth,
HDR-BRT is a safe method with low complication rates.
In our experience, about 10% of the patients undergo-
ing HDR-BRT showed complications, one (2%) bacterial
meningitis and two (4%) haemorrhages (one of them
with fatal extent) were observed in these patients. These
ﬁve factors contribute to the safety and feasibility of
HDR-BRT in the management of recurrent glioblastoma
following primary surgery and radiochemotherapy.
The incidence of radionecrosis was remarkably low in
our HDR-BRT group. In studies reporting results of
125I seed implantation, 40–50% manifested symptomatic
Archavlis E, Tselis N, Birn G, et al. BMJ Open 2013;3:e002262. doi:10.1136/bmjopen-2012-002262 7
Salvage therapies in recurrent glioblastoma
  group.bmj.com  on May 13, 2013 - Published by  bmjopen.bmj.com Downloaded from focal radiation damage. The fact that we used stereotac-
tically implanted catheters which were removed after
completion of reirradiation instead of seeds which may
slightly migrate over time may play an important role in
reducing radionecrosis.
Re-resection still remains in our hands as a very
important palliative care for selected patients. The deci-
sion to treat with surgery was dependent mainly on
whether eloquent brain areas were affected and based
on morphology and topography of the tumour progres-
sion in relation to speech, motor areas, brainstem and
sylvic ﬁssure. Ideally, with technological support (func-
tional MR, diffusion tenson imaging and ﬁbre tracking),
we can detect and locate the exact position of brain
functions before deciding to perform tumour resection,
allowing us to recommend surgery only in those patients
with the prospect of radical or grossly subtotal resection.
This point is of utmost importance in order to minimise
morbidity and mortality and to maximise postoperative
quality of life.
Despite the fact that the chance of survival was improved
by further surgical treatment or HDR-BRT, early recur-
rence after gross total removal and radiochemotherapy
and early second recurrence after either HDR-BRT or
re-resection, remained poor prognostic factors for overall
survival in patients with recurrent glioblastoma. Further
research should therefore focus on adjuvant treatment
after resection of glioblastoma. In fact, many chemothera-
peutic agents, either as single agents or in combination,
have been used to treat recurrent malignant gliomas.
Temozolomide, procarbazin, lomustin and vincristin
(PCV) and bevacizumab are some of the treatment
options.
4 Erlotinib and other epidermal growth factor
receptor (EGFR) inhibitors have been studied in combin-
ation with radiation therapy.
30 A recent study demon-
strated the survival beneﬁt of vaccine therapy in relapsed
tumours.
31 Alternatively, small trials reported that a
tumour B cell hybidoma vaccine against tumour stem cells
elicited a speciﬁc tumour immune reaction, thus enhan-
cing immune response to the disease
32 and results from
the larger trials might identify a new avenue in the area of
adjuvant treatment in the future.
The encouraging results of HDR-BRT including sur-
vival prolongation stress the need for randomised phase
2 trials to address the role of HDR-BRT in the recurrent
setting.The fact that SRS is not recommended for
lesions >40 mm in diameter
26 and given the extent of
recurrent tumours, constitute HDR-BRT more applic-
able in this patient population due to the fact that SRS
is not recommended for lesions >40 mm in diameter
26
and the fulﬁllment of this restriction would immensely
limit patients' eligibility for treatment in extended recur-
rent tumours.
Weaknesses
Our study design was not without pitfalls: non-
randomisation regarding choices of treatment, and
selection bias. Patients eligible for surgery may be
usually better than those who are not candidates and
this may bias the results towards a better outcome. The
lack of prospectivity and randomisation condemn this
study to low statistical power in demonstrating a beneﬁt
of one therapy relative to another. However, a rando-
mised controlled trial might be difﬁcult to conduct
given the obvious symptomatic beneﬁts that surgery can
provide in many instances and the survival beneﬁts that
HDR-BRT has shown in our recent retrospective
studies.
14 15 Another limitation of our study is that data
on therapies administered after reoperation or brachy-
therapy were not included in our analysis. Given the
overall lack of efﬁcacy of phase II tested therapies for
recurrent gliomas, their contribution to postoperative
survival is likely to have been negligible.
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CONCLUSIONS
HDR-BRT achieved in this retrospective study a better
survival outcome in comparison to those seen with
re-resection or ddTMZ in the treatment of glioblastoma
recurrence after primary surgery and radiochemother-
apy. Salvage treatment of recurrent GBM remains a
challenging issue for neurosurgeons and needs a multi-
disciplinary approach including radiotherapists and
oncologists. However, a persevering attitude is manda-
tory in the management of glioblastoma to improve the
chance of longevity for recurrent disease. The fact that
HDR-BRT can be delivered percutaneously under local
anaesthesia and mild sedoanalgesia and its relative safety
render it a promising treatment option which should
be further evaluated in patients with glioblastoma
recurrence.
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